Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Greenovation Biotech GmbH. (3/9/15). "Press Release: Greenovation Successfully Completes Preclinical Toxicology Studies of alpha–Galactosidase". Freiburg.

Organisation Organisation Greenovation Biotech GmbH
Products Product Moss-aGal (recombinant human alpha-galactosidase)
  Product 2 preclinical research
Person Person Frischmuth, Thomas (Panatecs 201205– Managing Director + Greenovation 201105 Managing Director + baseclick)

Greenovation Biotech GmbH has successfully completed GLP toxicology studies in non-human primates, and has demonstrated that the moss-aGal (Agalsidase) is safe and very well-tolerated in repeated high dose administrations. The plant-based cGMP manufacturing process resulted in a high yield batch of moss-aGal to be used in upcoming clinical trials.

The GLP toxicology studies in non-human primates demonstrate the moss-aGal to be safe and well tolerated at a dose of 5 to 10 fold higher than the expected human therapeutic dose. In summary, the study investigated intravenous administration of moss-aGal via two 40-minute infusions at doses of either 0 or 5 mg/kg to male and female cynomolgus monkeys. As a result, the study concludes that moss-aGal was very well tolerated under the given study conditions and did not reveal any treatment-related findings. Thus, the no-observed-adverse-effect-level (NOAEL) is considered to be the tested dose level of 5 mg/kg.

“The successful cGMP manufacturing of moss-aGal in the moss expression plattform and the successfully concluded toxicology studies are major developmental milestones for Greenovations alpha-Galactosidase program. Currently we are working on our regulatory package for a Phase I/II clinical trial which includes Fabry Disease patients,“ stated Dr. Thomas Frischmuth, CEO of Greenovation. “Achieving a proprietary, commercially viable manufacturing process of alpha-Galactosidase demonstrates the successful development of Greenovation into a biopharmaceutical company.”

About Greenovation Biotech GmbH

Greenovation develops next generation biopharmaceuticals in particular in rare disease indications. Human alpha-Galactosidase is the company’s lead product being developed as enzyme-replacement therapy (ERT) for Fabry Disease. Results of the recently completed pre-clinical program clearly indicate superiority features with respect to pharmacokinetics (delayed clearance), pharmacodynamics and biodistribution. A multi-center clinical Phase I/II study with this candidate will be undertaken in Europe.

Greenovation’s development pipeline further includes glucocerebrosidase (glucerase, for ERT of Gaucher’s disease), complement factor H (to treat atypical HUS), antibody (IgG) programs for enhanced ADCC as well as growth factors (FGF7/KGF, EGF, HGF) for various applications.

Contact and further information

Greenovation Biotech GmbH
Manon Bartusel
Tel. +49 (0)761 470 99 0

Record changed: 2017-04-02


Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Greenovation Biotech GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px

» top